Document ID: chunk:federal_register_of_legislation:F2022L01121:reg:9
Version: federal_register_of_legislation:F2022L01121
Segment Type: reg
Provision Reference: reg 9
Character Range: 3151–5511

9               Factors that must exist
At least one of the following factors must exist before it can be said that, on the balance of probabilities, steatohepatitis or death from steatohepatitis is connected with the circumstances of a person's relevant service:
(1)          having diabetes mellitus at the time of the clinical onset of steatohepatitis;
(2)          being obese at the time of the clinical onset of steatohepatitis;
Note: being obese is defined in the Schedule 1 – Dictionary.
(3)          having rapid weight loss causing protein-calorie malnutrition within the 18 months before the clinical onset of steatohepatitis;
Note: rapid weight loss is defined in the Schedule 1 – Dictionary.
(4)          undergoing jejunoileal bypass surgery before the clinical onset of steatohepatitis;
(5)          receiving total parenteral nutrition for at least 6 months within the 1 year before the clinical onset of steatohepatitis;
Note: total parenteral nutrition is defined in the Schedule 1 – Dictionary.
(6)          having dyslipidaemia at the time of the clinical onset of steatohepatitis;
Note: dyslipidaemia is defined in the Schedule 1 – Dictionary.
(7)          for males, consuming at least 75 kilograms of alcohol within any 5 year period before the clinical onset of steatohepatitis;
Note: Alcohol consumption is calculated utilising the Australian Standard of ten grams of alcohol per standard alcoholic drink.
(8)          for females, consuming at least 40 kilograms of alcohol within any 5 year period before the clinical onset of steatohepatitis;
Note: Alcohol consumption is calculated utilising the Australian Standard of ten grams of alcohol per standard alcoholic drink.
(9)          taking irinotecan for at least the 30 days before the clinical onset of steatohepatitis;
(10)      taking a drug specified in the Schedule 2 - Drugs of this Instrument, that cannot be ceased or substituted, for at least the 30 days before the clinical onset of steatohepatitis;
(11)      taking a drug that cannot be ceased or substituted and which is associated in the individual with:
(a)          the development of steatohepatitis within 30 days of first taking the drug; and
(b)          the redevelopment of steatohepatitis on rechallenge with the same drug;
(12)      inability to obtain appropriate clinical management for steatohepatitis.